OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
Sara Elena Rebuzzi, Giuseppe Luigi Banna, Veronica Murianni, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5517-5517
Open Access | Times Cited: 13
Sara Elena Rebuzzi, Giuseppe Luigi Banna, Veronica Murianni, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5517-5517
Open Access | Times Cited: 13
Showing 13 citing articles:
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
Ioannis A. Voutsadakis
Current Oncology (2022) Vol. 29, Iss. 3, pp. 1390-1407
Open Access | Times Cited: 23
Ioannis A. Voutsadakis
Current Oncology (2022) Vol. 29, Iss. 3, pp. 1390-1407
Open Access | Times Cited: 23
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
Aruni Ghose, Patricia Lapitan, Vedika Apte, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 6, pp. 633-646
Closed Access | Times Cited: 4
Aruni Ghose, Patricia Lapitan, Vedika Apte, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 6, pp. 633-646
Closed Access | Times Cited: 4
Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab
Gustav Hjorthén, Fernanda Costa Svedman, Karin Holmsten, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Open Access
Gustav Hjorthén, Fernanda Costa Svedman, Karin Holmsten, et al.
Urologic Oncology Seminars and Original Investigations (2025)
Open Access
Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art
Gianluigi Califano, I. Ouzaïd, P. Lainé-Caroff, et al.
Current Oncology (2022) Vol. 29, Iss. 2, pp. 687-697
Open Access | Times Cited: 17
Gianluigi Califano, I. Ouzaïd, P. Lainé-Caroff, et al.
Current Oncology (2022) Vol. 29, Iss. 2, pp. 687-697
Open Access | Times Cited: 17
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma
Brigida Anna Maiorano, Giovanni Schinzari, Carmine Carbone, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Brigida Anna Maiorano, Giovanni Schinzari, Carmine Carbone, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy
Michele Dionese, Umberto Basso, Francesco Pierantoni, et al.
Future Science OA (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 8
Michele Dionese, Umberto Basso, Francesco Pierantoni, et al.
Future Science OA (2023) Vol. 9, Iss. 7
Open Access | Times Cited: 8
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Matteo Ferro, Felice Crocetto, Octavian Sabin Tătaru, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 5, pp. 574-583
Closed Access | Times Cited: 5
Matteo Ferro, Felice Crocetto, Octavian Sabin Tătaru, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 5, pp. 574-583
Closed Access | Times Cited: 5
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab
Satoshi Katayama, Takehiro Iwata, Tasushi Kawada, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 42, Iss. 3, pp. 70.e11-70.e18
Closed Access | Times Cited: 4
Satoshi Katayama, Takehiro Iwata, Tasushi Kawada, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 42, Iss. 3, pp. 70.e11-70.e18
Closed Access | Times Cited: 4
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access | Times Cited: 1
Caroline Taylor, Kamai M. Patterson, Devira Friedman, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 3071-3071
Open Access | Times Cited: 1
Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation
Gregor Duwe, Lukáš Müller, Christian Ruckes, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2482-2482
Open Access | Times Cited: 3
Gregor Duwe, Lukáš Müller, Christian Ruckes, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2482-2482
Open Access | Times Cited: 3
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
Marco Audisio, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 174, pp. 103682-103682
Closed Access | Times Cited: 5
Marco Audisio, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 174, pp. 103682-103682
Closed Access | Times Cited: 5
Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic
E. López-Anglada Fernández, J.C. Angulo, José I. López, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 493-493
Open Access | Times Cited: 1
E. López-Anglada Fernández, J.C. Angulo, José I. López, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 493-493
Open Access | Times Cited: 1
Cofilin1 Is a Poorer Prognostic Biomarker and potential Immunotherapy in Systematic Pan-Cancer
Jin Yang, Cheng-Jie Qiu, Shan Zhong, et al.
Research Square (Research Square) (2022)
Open Access
Jin Yang, Cheng-Jie Qiu, Shan Zhong, et al.
Research Square (Research Square) (2022)
Open Access
